Corona vaccine syringe developed by Korean small and medium-sized companies approved by US FDA 20% increase in production effect

With the help of the government and Samsung Electronics, the syringes for the Corona 19 vaccine of a Korean small and medium-sized company that succeeded in mass production are expected to gain momentum in exports with the approval of the Food and Drug Administration (FDA).

Poonglim Pharmatech, a medical device manufacturer in Gunsan, Jeollabuk-do, said on the 17th that “A syringe for Corona 19 vaccine with LDV (Low Dead Volume) technology has been approved by the US FDA.”

Earlier, Poonglim Pharmatech obtained an approval for use in Korea from the Ministry of Food and Drug Safety for this syringe, and then submitted an urgent use approval request to the US FDA last month.

Poonglim Pharmatech’s syringe passed the performance test for the minimum injection residual amount of a US pharmaceutical company, and also met the performance requirements.

This syringe is characterized by minimizing the amount of vaccine left in the syringe when administering the drug. The amount of remaining injections per minute is more than 84 microliters (μL) in the general syringe, but the injection of Poonglim was minimized to 4 μL.

With a regular syringe, you can inoculate up to 5 times per bottle of vaccine, but if you use Poonglim’s syringe, more than 6 times per bottle is possible. In other words, it has the effect of significantly reducing the loss of the remaining injection amount and increasing the production of the Corona 19 vaccine by an additional 20%.

Poonglim has applied for domestic technology patents and design patents related to the minimum injection amount and safety guard, and is also applying for international patents in the United States and the European Union (EU).

Poonglim has established a smart factory mass production system that can produce more than 10 million these syringes per month.